Nucleic Acids Research, 1991, Vol. 19, No. 2 319-325
© 1991
MOLECULAR BIOLOGY |
The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines
Celltech Ltd 216 Bath Road, Slough, SL1 4EN, UK
*To whom correspondence should be addressed
Received October 9, 1990. Revised December 10, 1990. Accepted December 10, 1990.
Vectors expressing adenovirus 5 E1A or a domain 2 mutant E1A were introduced into CHO-K1 cells in order to transactivate the hCMV-MIE promoter in transient and stable transfections. Expression from the hCMV promoter was efficiently activated by both wild-type and mutant E1A in contrast to other viral promoters such as the SV40 early promoter which are repressed by E1 A. E1A genes expressed from a strong promoter were inhibitory to the growth of CHO cells. Nevertheless, by the use of a weaker promoter, it was possible to Isolate stably transfected cell lines containing a level of E1A compatible with both continued cell growth and significant transactlvation of the hCMV promoter. By this means we have generated cell lines secreting tissue Inhibitor of metallo-proteinases (TIMP) at levels approaching those previously attained using gene amplification. CHO cell lines constitutively expressing wild-type and mutant E1A genes have been derived which can serve as new host cell lines for transient expression and efficient stable expression without gene amplification.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Olafsen, V. E. Kenanova, G. Sundaresan, A.-L. Anderson, D. Crow, P. J. Yazaki, L. Li, M. F. Press, S. S. Gambhir, L. E. Williams, et al. Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging Cancer Res., July 1, 2005; 65(13): 5907 - 5916. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Clark, R. Pankov, M. A. Travis, J. A. Askari, A. P. Mould, S. E. Craig, P. Newham, K. M. Yamada, and M. J. Humphries A specific {alpha}5{beta}1-integrin conformation promotes directional integrin translocation and fibronectin matrix formation J. Cell Sci., January 15, 2005; 118(2): 291 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Olafsen, G. J. Tan, C.-w. Cheung, P. J. Yazaki, J. M. Park, J. E. Shively, L. E. Williams, A. A. Raubitschek, M. F. Press, and A. M. Wu Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting Protein Eng. Des. Sel., April 1, 2004; 17(4): 315 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Fortenberry and J. M. Chirgwin The Propeptide Is Nonessential for the Expression of Human Cathepsin D J. Biol. Chem., April 28, 1995; 270(17): 9778 - 9782. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schorey, S. Fortenberry, and J. Chirgwin Lysine residues in the C-terminal lobe and lysosomal targeting of procathepsin D J. Cell Sci., January 5, 1995; 108(5): 2007 - 2015. [Abstract] [PDF] |
||||
![]() |
A. P. F. Coe, J. A. Askari, A. D. Kline, M. K. Robinson, H. Kirby, P. E. Stephens, and M. J. Humphries Generation of a Minimal alpha 5beta 1 Integrin-Fc Fragment J. Biol. Chem., September 14, 2001; 276(38): 35854 - 35866. [Abstract] [Full Text] [PDF] |
||||



